Introduction The anti-CD20 monoclonal antibodies, rituximab (RTX) and ocrelizumab (OCRE), are used routinely for the treatment of neuroimmunological diseases. However, infusion-related reactions (IRRs) are common, and their underlying mechanisms are not well defined. Objectives Our […]
Introduction In recent years there has been an increase in the number of disease-modifying drugs (DMDs) approved for multiple sclerosis (MS). The evidence of their safety and efficacy has been obtained through several phase III […]
Introduction This study explores the association between multiple sclerosis (MS) and other autoimmune diseases, including myasthenia gravis (MG), autoimmune encephalitis (AE), and demyelinating polyneuropathies such as combined central and peripheral demyelination (CCPD), chronic inflammatory demyelinating […]
Introduction Multiple sclerosis can be associated with a range of rheumatic processes. Behçet disease is a relapsing, multisystemic, immune-mediated chronic vasculitic disorder of unknown aetiology, whose symptoms overlap with those of many autoinflammatory processes. Sarcoidosis […]
Introduction Multiple sclerosis (MS) may be associated with a range of rheumatic diseases. Rheumatoid arthritis is a chronic inflammatory disease typically affecting small- and medium-size joints. MS has been associated with antiphospholipid syndrome. Development The […]
Introduction Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. An association has been established […]
Introduction The eye is a complex organ that can present complications related to autoimmune diseases, including multiple sclerosis (MS). Ocular manifestations may act as early indicators of autoimmune diseases, and their early diagnosis and treatment […]
Introduction Autoimmune dermatological diseases have a prevalence greater than 2% in the general population, sometimes as a primary disorder and other times within a context of systemic involvement. Comorbidity with multiple sclerosis (MS) has been […]
Introduction The efficacy and safety of alemtuzumab for patients with relapsing–remitting multiple sclerosis (RRMS) have been demonstrated in clinical trials. However, due to the limitations of these studies, it is important to assess the effects […]
Introduction The global prevalence of multiple sclerosis (MS) has increased in recent decades. However, there is a need for updated prevalence data for Spain. Objective To analyze the prevalence of MS in Spain using data […]